Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
Discontinued
Reference number: GID-TA10583
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer have been revised. It is anticipated that the appraisal will begin in mid-June 2023 when we will write to you about how you can get involved.